Health Resource Utilization and Associated Health Care Costs of Biologic Disease-Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis (2024)

Sewerin, P., Borchert, K., Meise, D., Schneider, M., & Mahlich, J. (2022). Health Resource Utilization and Associated Health Care Costs of Biologic Disease-Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis. , 74(9), 1435-1443. https://doi.org/10.1002/acr.24598

Sewerin, Philipp ; Borchert, Kathrin ; Meise, Dominic et al. / Health Resource Utilization and Associated Health Care Costs of Biologic Disease-Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis. in: . 2022 ; Band 74, Nr. 9. S. 1435-1443.

@article{bd4dfef4d55f4411a128fa5accb4472c,

title = "Health Resource Utilization and Associated Health Care Costs of Biologic Disease-Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis",

abstract = "Objective: To investigate health care costs associated with biologic disease-modifying antirheumatic drugs (bDMARDs) in a German real-world cohort of adult biologics-naive patients with psoriatic arthritis (PsA). Methods: Claims data from the Institute for Applied Health Research Berlin (InGef) research database for patients with a PsA diagnosis and bDMARD claims record (index date) between January 1, 2014, and December 31, 2017, and no bDMARD prescriptions for 365 days before the index date were retrospectively analyzed. Primary outcomes were determination of health care resource utilization and associated annual health care costs for overall and individual bDMARDs in the 12-month pre-index and post-index periods. These outcomes were compared between persistent and nonpersistent groups. Nonpersistence was defined as treatment gap or switch to a bDMARD other than the index therapy. Results: Among 10,954 patients with a PsA diagnosis, 348 were eligible. Although mean ± SD post-index costs were significantly higher in the persistent group than the nonpersistent group (€27,869 ± 8,001 versus €21,897 ± 10,600, P < 0.001) due to higher bDMARD acquisition costs (€23,996 ± 4,818 versus €16,427 ± 9,033, P < 0.001), persistence reduced inpatient treatment costs (–€760), outpatient treatment costs (–€192), other drug costs (–€724), and sick leave costs (–€601). Conclusion: Although initiation of bDMARDs increased the total health care costs irrespective of persistence status, partial cost offsets were observed in the persistent patient population.",

author = "Philipp Sewerin and Kathrin Borchert and Dominic Meise and Matthias Schneider and J{\"o}rg Mahlich",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology.",

year = "2022",

month = sep,

doi = "10.1002/acr.24598",

language = "English",

volume = "74",

pages = "1435--1443",

journal = "Arthritis Care & Research",

issn = "2151-464X",

publisher = "Wiley-Blackwell",

number = "9",

}

Sewerin, P, Borchert, K, Meise, D, Schneider, M & Mahlich, J 2022, 'Health Resource Utilization and Associated Health Care Costs of Biologic Disease-Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis', , Jg. 74, Nr. 9, S. 1435-1443. https://doi.org/10.1002/acr.24598

Health Resource Utilization and Associated Health Care Costs of Biologic Disease-Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis. / Sewerin, Philipp; Borchert, Kathrin; Meise, Dominic et al.

in: , Band 74, Nr. 9, 09.2022, S. 1435-1443.

Veröffentlichungen: Beitrag in Fachzeitschrift › Artikel › Peer Reviewed

TY - JOUR

T1 - Health Resource Utilization and Associated Health Care Costs of Biologic Disease-Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis

AU - Sewerin, Philipp

AU - Borchert, Kathrin

AU - Meise, Dominic

AU - Schneider, Matthias

AU - Mahlich, Jörg

N1 - Publisher Copyright:© 2021 The Authors. Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

PY - 2022/9

Y1 - 2022/9

N2 - Objective: To investigate health care costs associated with biologic disease-modifying antirheumatic drugs (bDMARDs) in a German real-world cohort of adult biologics-naive patients with psoriatic arthritis (PsA). Methods: Claims data from the Institute for Applied Health Research Berlin (InGef) research database for patients with a PsA diagnosis and bDMARD claims record (index date) between January 1, 2014, and December 31, 2017, and no bDMARD prescriptions for 365 days before the index date were retrospectively analyzed. Primary outcomes were determination of health care resource utilization and associated annual health care costs for overall and individual bDMARDs in the 12-month pre-index and post-index periods. These outcomes were compared between persistent and nonpersistent groups. Nonpersistence was defined as treatment gap or switch to a bDMARD other than the index therapy. Results: Among 10,954 patients with a PsA diagnosis, 348 were eligible. Although mean ± SD post-index costs were significantly higher in the persistent group than the nonpersistent group (€27,869 ± 8,001 versus €21,897 ± 10,600, P < 0.001) due to higher bDMARD acquisition costs (€23,996 ± 4,818 versus €16,427 ± 9,033, P < 0.001), persistence reduced inpatient treatment costs (–€760), outpatient treatment costs (–€192), other drug costs (–€724), and sick leave costs (–€601). Conclusion: Although initiation of bDMARDs increased the total health care costs irrespective of persistence status, partial cost offsets were observed in the persistent patient population.

AB - Objective: To investigate health care costs associated with biologic disease-modifying antirheumatic drugs (bDMARDs) in a German real-world cohort of adult biologics-naive patients with psoriatic arthritis (PsA). Methods: Claims data from the Institute for Applied Health Research Berlin (InGef) research database for patients with a PsA diagnosis and bDMARD claims record (index date) between January 1, 2014, and December 31, 2017, and no bDMARD prescriptions for 365 days before the index date were retrospectively analyzed. Primary outcomes were determination of health care resource utilization and associated annual health care costs for overall and individual bDMARDs in the 12-month pre-index and post-index periods. These outcomes were compared between persistent and nonpersistent groups. Nonpersistence was defined as treatment gap or switch to a bDMARD other than the index therapy. Results: Among 10,954 patients with a PsA diagnosis, 348 were eligible. Although mean ± SD post-index costs were significantly higher in the persistent group than the nonpersistent group (€27,869 ± 8,001 versus €21,897 ± 10,600, P < 0.001) due to higher bDMARD acquisition costs (€23,996 ± 4,818 versus €16,427 ± 9,033, P < 0.001), persistence reduced inpatient treatment costs (–€760), outpatient treatment costs (–€192), other drug costs (–€724), and sick leave costs (–€601). Conclusion: Although initiation of bDMARDs increased the total health care costs irrespective of persistence status, partial cost offsets were observed in the persistent patient population.

UR - http://www.scopus.com/inward/record.url?scp=85131130534&partnerID=8YFLogxK

U2 - 10.1002/acr.24598

DO - 10.1002/acr.24598

M3 - Article

C2 - 33742791

AN - SCOPUS:85131130534

VL - 74

SP - 1435

EP - 1443

JO - Arthritis Care & Research

JF - Arthritis Care & Research

SN - 2151-464X

IS - 9

ER -

Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J. Health Resource Utilization and Associated Health Care Costs of Biologic Disease-Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis. . 2022 Sep;74(9):1435-1443. doi: 10.1002/acr.24598